Literature DB >> 8459226

Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients.

A Anichini1, C Maccalli, R Mortarini, S Salvi, A Mazzocchi, P Squarcina, M Herlyn, G Parmiani.   

Abstract

HLA-A2-restricted, CD3+, CD8+, alpha/beta+ cytotoxic T cell (CTL) clones were isolated from peripheral blood (PBL) or tumor infiltrating lymphocytes (TIL) of two HLA-A2+ melanoma patients (9742 and 5810), to evaluate the possible recognition of autologous melanoma and of allogeneic HLA-A2-matched normal melanocytes. These CTL clones lysed not only fresh and cultured autologous melanoma cells, but also allogeneic HLA-A2+, but not HLA-A2-, normal melanocytes. The lysis of autologous neoplastic cells and of melanocytes could be inhibited by an anti-HLA-A2 monoclonal antibody (mAb). Lysis of the normal melanocytes was not dependent on the presence of human or fetal calf serum in the culture medium. HLA-A2-restricted CTL clones recognized not only proliferating melanocytes cultured in complete melanocyte medium, but also melanocytes made quiescent by culture for up to 6 d in a basal medium devoid of exogenous factors such as phorbol ester (O-tetradecanoyl phorbol 13-acetate [TPA]), epidermal growth factor, insulin, and pituitary extracts. Analysis of specificity of four CTL clones (A75, A83, A94, and 119) from patient 9742, performed on a panel of 39 targets, indicated that the three HLA-A2-restricted CTL (A75, A83, and A94) lysed all but one of nine allogeneic melanomas expressing the HLA-A2 molecule with no reactivity on nine HLA-A2- allogeneic melanomas. Only a few instances of borderline reactivity were seen by the same effectors on 21 targets of nonmelanocyte lineage, including 12 carcinomas of different histology, four Epstein-Barr virus-transformed B cells (lymphoblastoid cell lines [LCL]), including the autologous LCL, four lines of normal fibroblasts, and normal kidney cells. Lack of reactivity on allogeneic targets of nonmelanocyte lineage occurred in spite of expression of HLA-A2 on 14 of these targets as determined by conventional tissue typing and cytofluorimetric analysis with four different anti-HLA-A2 mAb. These data indicate that tissue-related antigens can be expressed on normal and neoplastic cells of the melanocyte lineage and can be recognized in association with HLA-A2 by CTL clones from melanoma patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8459226      PMCID: PMC2190978          DOI: 10.1084/jem.177.4.989

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  31 in total

1.  The use of hybrid hybridomas to target human cytotoxic T lymphocytes.

Authors:  A Lanzavecchia; D Scheidegger
Journal:  Eur J Immunol       Date:  1987-01       Impact factor: 5.532

Review 2.  HLA-B27 and HLA-A2 subtypes: structure, evolution and function.

Authors:  J A López de Castro
Journal:  Immunol Today       Date:  1989-07

3.  Cytotoxic T lymphocyte clones from peripheral blood and from tumor site detect intratumor heterogeneity of melanoma cells. Analysis of specificity and mechanisms of interaction.

Authors:  A Anichini; A Mazzocchi; G Fossati; G Parmiani
Journal:  J Immunol       Date:  1989-05-15       Impact factor: 5.422

4.  The monoclonal antibody CR11-351 discriminates HLA-A2 variants identified by T cells.

Authors:  C Russo; A K Ng; M A Pellegrino; S Ferrone
Journal:  Immunogenetics       Date:  1983       Impact factor: 2.846

5.  Expression of melanoma-associated antigens in rapidly dividing human melanocytes in culture.

Authors:  M Herlyn; U Rodeck; M Mancianti; F M Cardillo; A Lang; A H Ross; J Jambrosic; H Koprowski
Journal:  Cancer Res       Date:  1987-06-15       Impact factor: 12.701

6.  Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody.

Authors:  T Kawamoto; J D Sato; A Le; J Polikoff; G H Sato; J Mendelsohn
Journal:  Proc Natl Acad Sci U S A       Date:  1983-03       Impact factor: 11.205

7.  Pigmentation-associated glycoprotein of human melanomas and melanocytes: definition with a mouse monoclonal antibody.

Authors:  T M Thomson; M J Mattes; L Roux; L J Old; K O Lloyd
Journal:  J Invest Dermatol       Date:  1985-08       Impact factor: 8.551

8.  Phenotypic heterogeneity of melanoma. Relation to the differentiation program of melanoma cells.

Authors:  A N Houghton; F X Real; L J Davis; C Cordon-Cardo; L J Old
Journal:  J Exp Med       Date:  1987-03-01       Impact factor: 14.307

9.  Cell surface antigens of human melanocytes and melanoma. Expression of adenosine deaminase binding protein is extinguished with melanocyte transformation.

Authors:  A N Houghton; A P Albino; C Cordon-Cardo; L J Davis; M Eisinger
Journal:  J Exp Med       Date:  1988-01-01       Impact factor: 14.307

10.  Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells.

Authors:  M L Dustin; T A Springer
Journal:  J Cell Biol       Date:  1988-07       Impact factor: 10.539

View more
  38 in total

Review 1.  T-cell recognition of self peptides as tumor rejection antigens.

Authors:  Y Kawakami; S A Rosenberg
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

Review 2.  Cancer gene and immunotherapy: recent developments.

Authors:  P Jantscheff; R Herrmann; C Rochlitz
Journal:  Med Oncol       Date:  1999-07       Impact factor: 3.064

Review 3.  Melanoma vaccines. Current status and future prospects.

Authors:  P Hersey
Journal:  Drugs       Date:  1994-03       Impact factor: 9.546

Review 4.  Direct identification of tumor-associated peptide antigens.

Authors:  V H Engelhard
Journal:  Springer Semin Immunopathol       Date:  1996

5.  Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens.

Authors:  O Türeci; U Sahin; C Zwick; M Koslowski; G Seitz; M Pfreundschuh
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

Review 6.  Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I.

Authors:  N P Restifo; Y Kawakami; F Marincola; P Shamamian; A Taggarse; F Esquivel; S A Rosenberg
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1993-10

7.  Vitiligo- and melanoma-associated hypopigmentation: a similar appearance but a different mechanism.

Authors:  O Merimsky; Y Shoenfeld; G Yecheskel; S Chaitchik; E Azizi; P Fishman
Journal:  Cancer Immunol Immunother       Date:  1994-06       Impact factor: 6.968

8.  Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.

Authors:  Y Kawakami; S Eliyahu; C H Delgado; P F Robbins; L Rivoltini; S L Topalian; T Miki; S A Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

9.  Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen.

Authors:  M J Maeurer; S M Gollin; D Martin; W Swaney; J Bryant; C Castelli; P Robbins; G Parmiani; W J Storkus; M T Lotze
Journal:  J Clin Invest       Date:  1996-10-01       Impact factor: 14.808

10.  Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC- restricted T cell receptor-like specificity.

Authors:  Galit Denkberg; Cyril J Cohen; Avital Lev; Patrick Chames; Hennie R Hoogenboom; Yoram Reiter
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.